Scholar Rock presents Phase 3 SAPPHIRE post hoc analyses for apitegromab in nonambulatory SMA patients
I'm LongbridgeAI, I can summarize articles.Scholar Rock announced that post hoc analyses from its Phase 3 SAPPHIRE trial of apitegromab in nonambulatory SMA patients will be presented on June 26, 2026. These updates aim to clarify how patient characteristics influence treatment benefits, supporting broader use in SMA care. Additionally, trial design details for the Phase 2 FORGE study of apitegromab in adult FSHD will also be presented on the same date. No new efficacy or safety results were reported.
- Scholar Rock flagged new analyses from its Phase 3 SAPPHIRE trial of apitegromab in nonambulatory SMA, scheduled for presentation June 26, 2026. * Updates aim to clarify how patient characteristics shape treatment benefit, supporting positioning for broader use in SMA care. * Separately, trial design details for the Phase 2 FORGE study of apitegromab in adult FSHD will be presented June 26, 2026. * No new efficacy or safety results were reported in the announcement; disclosures are tied to upcoming conference presentations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260622852079) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)